Why the study?
Does disopyramide phosphate cause torsade de pointes in patients with recurrent atrial fibrillation?
Does disopyramide phosphate cause torsade de pointes in patients with recurrent atrial fibrillation?
Disopyramide phosphate can cause torsade de pointes, particularly when used with other QT-prolonging agents like amiodarone or in patients with severe repolarization delay.
Answers are grounded in this paper and cite their sources.
Disopyramide may provoke torsade de pointes at conventional doses in atrial fibrillation; case reports leave open incidence and risk predictors.
• Recurrent ventricular tachycardia (torsade de pointes) is a serious and sometimes fatal arrhythmia occurring usually with quinidine therapy. Four patients experienced ventricular tachycardia after receiving conventional doses of disopyramide phosphate (600 mg/day) for recurrent atrial fibrillation—two of them in combination with amiodarone hydrochloride. Isoproterenol hydrochloride infusion was effective in three patients, while ventricular pacing promptly abolished ventricular ectopic beats and the ventricular tachycardia in the fourth patient.Torsade de pointesis more likely to occur in patients with severe repolarization delay and sinus bradycardia or atrioventricular block, and its appearance in four patients within a period of nine months after the introduction of disopyramide treatment in our service raises the possibility that this is not a rare complication of this drug, especially if used in combination with other QT interval-prolonging agents. (Arch Intern Med1981;141:946-947)
No takes yet. Share an insight, caveat, or question.
Dan Tzivoni (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: